FILING ANALYSIS · MONDAY, NOVEMBER 16
Iambic Therapeutics, Inc. IAM — 8-K: Results of Operations and Financial Condition
positive
Iambic Therapeutics reported strong Q3 financial results, including $24 million in collaboration revenue and a cash position of $252 million, with a pro-forma cash position of $455 million after their IPO and AbbVie upfront payments. The company also announced positive clinical data for its IAM1363 candidate and plans to initiate a registrational study in 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →